Chris Seeger Appointed to the Humira MDL Executive Committee

Seeger Weiss founding partner, Chris Seeger, has been appointed to the MDL Executive Committee of pending antitrust litigation against drug maker AbbVie for the company’s action regarding popular immune drug, Humira. A number of lawsuits against AbbVie and other pharmaceutical companies have been brought by insurance clients and other end-payers due to accusations that the […]

June 7, 2019

Chris Seeger headshot

Seeger Weiss founding partner, Chris Seeger, has been appointed to the MDL Executive Committee of pending antitrust litigation against drug maker AbbVie for the company’s action regarding popular immune drug, Humira.

A number of lawsuits against AbbVie and other pharmaceutical companies have been brought by insurance clients and other end-payers due to accusations that the companies engaged in unfair competitive acts regarding Humira and its related patents. These cases have been consolidated into multidistrict litigation (MDL) in the U.S. District Court for the Northern District of Illinois under Judge Manish S. Shah.

Judge Shah has appointed Seeger Weiss founding partner, Chris Seeger to the Executive Committee for the Humira MDL. The MDL Executive Committee is comprised of nine attorneys which includes three co-lead counsels from New York, California and Massachusetts and six plaintiff’s executive committee members from Louisiana, New York, Pennsylvania, and California.

The lawsuits claim that AbbVie engaged in improper anti-competitive action to protect its market exclusivity of autoimmune drug Humira. The lawsuits have been brought by insurance and managed care payers who may have been improperly forced to pay higher costs for Humira versus similar medications which were blocked from the U.S. market.

Humira is a flagship drug of AbbVie and brings the company over $20 billion per year in revenue. It is used for a number of autoimmune disorders including Rheumatoid Arthritis and is the best-selling medication of its type. Outside of the U.S., Humira faces competition from biosimilar medications but AbbVie has been successful in preventing U.S. competition with a web of over 100 patents that surround the medication.

Related News

September 22, 2023
Seeger Weiss Represents City of Chicago in New PCB Lawsuit Against Monsanto

Earlier this week, the City of Chicago filed a lawsuit against Monsanto and other chemical companies seeking damages for widespread contamination of its waterways caused by Polychlorinated biphenyls (PCBs), highly toxic and dangerous chemical compounds known to accumulate in the human body and cause serious health effects. Plaintiffs allege that Monsanto intentionally misled the public […]

Read More
September 15, 2023
Seeger Weiss Files First Lead Cable Class Action Lawsuit against Verizon

Seeger Weiss filed the first class action lawsuit against Verizon on behalf of utility workers over the company’s toxic lead-sheathed cables. Plaintiffs allege that Verizon knowingly left lead cables in place, exposing thousands of utility workers directly to dangerous levels of lead and allowing the cables to contaminate the surrounding environment. “For decades, Verizon and […]

Read More
September 7, 2023
Seeger Weiss Announces Settlement with Philips to Resolve Economic Loss Claims for Recalled CPAPs, Bi-PAPs, And Ventilators

Today, Seeger Weiss founding partner Chris Seeger, who serves as co-lead counsel in the Philips Recalled CPAP, Bi-Level Pap, and Mechanical Ventilator Products Litigation, announced a settlement worth a minimum of $479M on behalf of device users who purchased or rented recalled devices and payers who reimbursed users for the cost of recalled devices. “This […]

Read More